- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
- Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
- Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
- Tarsus to Participate at Upcoming Investor Conferences
- Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
- Tarsus Announces Pricing of $100.0 Million Public Offering
- Tarsus Announces Proposed $100.0 Million Public Offering
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
More ▼
Key statistics
On Monday, Tarsus Pharmaceuticals Inc (TARS:NSQ) closed at 38.73, -8.87% below its 52-week high of 42.50, set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.32 |
---|---|
High | 39.48 |
Low | 37.86 |
Bid | 36.00 |
Offer | 39.80 |
Previous close | 38.24 |
Average volume | 716.51k |
---|---|
Shares outstanding | 37.78m |
Free float | 33.21m |
P/E (TTM) | -- |
Market cap | 1.44bn USD |
EPS (TTM) | -4.72 USD |
Data delayed at least 15 minutes, as of May 20 2024 21:00 BST.
More ▼